Patent applications: Kite raises the game
This year, two precedential decisions by the US Court of Appeals for the Federal Circuit, Amgen v Sanofi (2021) and Juno Therapeutics v Kite Pharma (2021) have elevated the standards for satisfying the statutory requirement for enablement and written description of a patent application in the context of inventions that involve antibodies.
